The level of Alzheimer-associated neuronal thread protein in urine may be an important biomarker of mild cognitive impairment

Ma, Lina; Chen, Juan; Wang, Rong; Han, Ying; Zhang, Jingshuang; Dong, Wen; Zhang, Xu; Wu, Yali; Zhao, Zhigang

doi:10.1016/j.jocn.2014.10.011

Cited by 40 publications

(23 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with AD demonstrated elevated levels of AD7c-NTP in CSF and urine, and the elevated levels of AD7c-NTP were associated with the severity of dementia, i.e., very mild, mild or moderately severe AD. Several studies have suggested that AD7c-NTP is a useful biomarker, and may be widely used to screen the risk of elderly individuals with MCI and AD ( 96 – 99 ).…”

Section: Resultsmentioning

confidence: 99%

Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty

Ruan

Sancarlo

Greco

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

Cognitive frailty (CF) overlaps with early neuropathological alterations associated with aging-related major neurocognitive disorders, including Alzheimer's disease (AD). Fluid biomarkers for these pathological brain alterations allow for early diagnosis in the preclinical stages of AD, and for objective prognostic assessments in clinical intervention trials. These biomarkers may also be helpful in the screening of CF. The present study reviewed the literature and identified systematic reviews of cohort studies and other authoritative reports. The selection criteria for potentially suitable fluid biomarkers included: i) Frequent use in studies of fluid-derived markers and ii) evidence of novel measurement techniques for fluid-derived markers. The present study focused on studies that assessed these biomarkers in AD, mild cognitive impairment and non-AD demented subjects. At present, widely used fluid biomarkers include cerebrospinal fluid (CSF), total tau, phosphorylated tau and amyloid-β levels. With the development of novel measurement techniques and improvements in understanding regarding the mechanisms underlying aging-related major neurocognitive disorders, numerous novel biomarkers associated with various aspects of AD neuropathology are being explored. These include specific measurements of Aβ oligomer or monomer forms, tau proteins in the peripheral plasma and CSF, and novel markers of synaptic dysfunction, neuronal damage and apoptosis, neuronal activity alteration, neuroinflammation, blood brain barrier dysfunction, oxidative stress, metabolites, mitochondrial function and aberrant lipid metabolism. The proposed panels of fluid biomarkers may be useful in the early diagnosis of AD, prediction of the progression of AD from preclinical stages to the dementia stage, and the differentiation of AD from non-AD dementia. In combination with physical frailty, the present study surmised that these biomarkers may also be used as biomarkers for CF, thus contribute to discovering causes and informing interventions for cognitive impairment in individuals with CF.

show abstract

Section: Resultsmentioning

confidence: 99%

Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty

Ruan

Sancarlo

Greco

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…The sensitivity and specificity of this testing kit has been reported to reach 89.3% and 84.7%, respectively, in the diagnosis of AD (using National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria as the reference standard) [ 10 ]. It has been further demonstrated that urine AD7c-NTP level was increased even in mild cognitive impairment (MCI) individuals [ 11, 12 ]. However, the correlation between urine AD7c-NTP and validated AD pathological biomarkers, such as Aβ, has not been investigated.…”

Section: Introductionmentioning

confidence: 99%

Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer’s Disease and Mild Cognitive Impairment

Zhang

et al. 2017

JAD

View full text Add to dashboard Cite

Background:Expression of neuronal thread protein (NTP), which is considered to be related to neuritic sprouting and neuronal death, may be elevated in brain tissue, cerebrospinal fluid, and even urine in patients with Alzheimer’s disease (AD).Objective:In this study, we analyzed the correlation between urine AD-associated NTP (AD7c-NTP) level, and amyloid-β (Aβ) deposition, and clinical symptoms in AD and mild cognitive impairment (MCI).Methods:Twenty-two patients with mild to moderate AD and 8 subjects with MCI were recruited. Aβ deposition was measured with [11C]-labeled Pittsburgh compound B (PiB)-positron emission tomography (PET) in all participants. Urine AD7c-NTP levels were measured using enzyme-linked immunosorbent assay. Mini-Mental State Examination (MMSE) and Neuropsychiatric Inventory (NPI) were used to evaluate cognitive function and behavioral psychological symptoms, respectively.Results:Fourteen (63.6%) of AD patients and 2 (25.0%) of MCI subjects were Aβ positive on PiB-PET. There was a significant difference in urine AD7c-NTP level between Aβ positive (2.27±2.22 ng/ml) and negative (0.55±0.60 ng/ml) subjects (p = 0.018). Using 1.46 ng/ml as a cut-off value, 68.8% of Aβ positive subjects showed elevated urine AD7c-NTP level, and 92.9% of Aβ negative subjects showed normal urine AD7c-NTP level. There were no relationships between urine AD7c-NTP level and MMSE and total NPI scores. However, AD7c-NTP level positively correlated with agitation score on NPI.Conclusions:Urine AD7c-NTP had high specificity and moderate sensitivity in predicting Aβ deposition among patients with cognitive impairment. Furthermore, urine AD7c-NTP level strongly correlated with the symptom of agitation.

show abstract

“…Increased urinary levels of Alzheimer-associated neural thread protein (AD7c-NTP), a 41-kD membrane-associated phosphoprotein, have been reported in patients with AD and MCI. [5][6][7][8][9] These findings suggest that urinary AD7c-NTP could be a useful biomarker for identifying patients with MCI who have a high likelihood of conversion to AD. However, it remains unclear whether the levels of urinary AD7c-NTP among patients with aMCI are different from those with naMCI.…”

Section: Introductionmentioning

confidence: 89%

Comparison of Urinary Alzheimer-Associated Neural Thread Protein (AD7c-NTP) Levels Between Patients With Amnestic and Nonamnestic Mild Cognitive Impairment

Kim

et al. 2019

Am J Alzheimers Dis Other Demen

View full text Add to dashboard Cite

Urinary Alzheimer-associated neural thread protein (AD7c-NTP) is a potential biomarker of Alzheimer disease (AD) or mild cognitive impairment (MCI). It is still unclear whether the urinary levels of AD7c-NTP are different between patients with amnestic MCI (aMCI) and nonamnestic MCI (naMCI). The present study aimed to explore the differences in urinary levels of AD7c-NTP between patients with aMCI and naMCI. Forty-six patients with MCI were divided into aMCI group (n = 23) and naMCI group (n = 23). The mean level of urinary AD7c-NTP in the aMCI group (32.75 ± 10.0 µg/mL) was significantly higher than that in the naMCI group (25.34 ± 9.0 µg/mL; P = .011). As far as we know, the present study is the first to show that individuals with aMCI have higher levels of urinary AD7c-NTP than those with naMCI, suggesting that urinary AD7c-NTP may be a potential biomarker to help identify patients with aMCI and naMCI.

show abstract

The level of Alzheimer-associated neuronal thread protein in urine may be an important biomarker of mild cognitive impairment

Cited by 40 publications

References 20 publications

Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty

Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty

Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer’s Disease and Mild Cognitive Impairment

Comparison of Urinary Alzheimer-Associated Neural Thread Protein (AD7c-NTP) Levels Between Patients With Amnestic and Nonamnestic Mild Cognitive Impairment

Contact Info

Product

Resources

About